However, another compound that targets DGKα/β/γ isoforms (Compound A; unfortunately, to our knowledge, not yet commercially available) has been identified as highly effective in inducing apoptosis of a variety of cancer cells in vitro (Yamaki et al., 2019), and it would be interesting to determine whether this compound, as well as other newly identified DGK-specific inhibitors (Velnati et al., 2020, 2019), may have greater efficacy with trametinib in specifically targeting Ras-driven cancer cells relative to normal cells. Here, DGKE is linked to cancer.